Divergent approaches to rheumatoid arthritis-associated interstitial lung disease: a comparative analysis of international clinical practice guidelines. (PubMed, Rheumatol Int) - Oct 17, 2026 - "ACR/CHEST conditionally recommended mycophenolate, rituximab, azathioprine, and cyclophosphamide as first-line ILD therapies, whereas ALAT emphasized integrated control of articular and pulmonary disease, particularly with abatacept or rituximab. These differences reflect their scope, methodology, and limited RA-ILD-specific evidence. Prospective comparative studies are needed to inform more consistent care."
Clinical • Clinical guideline • Journal • Review • Fibrosis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology
|
|
Brenda Elena Varela; Gabriela Tabaj; María Otaola; Mario Chávez-López; Pedro Santos-Moreno; Ramiro A Gomez; Ricardo Blanco Alonso; Rodrigo Garcia-Salinas; Silvia Quadrelli
|